Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial

Élie Azoulay 1 Virginie Lemiale 2 Djamel Mokart 3 Saad Nseir 4 Laurent Argaud 5 Frédéric Pène 6 Loay Kontar Fabrice Bruneel 7 Kada Klouche 8, 9 François Barbier 10 Jean Reignier 11 Anabelle Stoclin Guillaume Louis 12 Jean-Michel Constantin 13 Julien Mayaux 14 Florent Wallet 15 Achille Kouatchet 16 Vincent Peigne 17 Pierre Perez Christophe Girault 18 Samir Jaber 8, 9 Johanna Oziel 19 Martine Nyunga Nicolas Terzi 20 Lila Bouadma 21 Christine Lebert 22 Alexandre Lautrette 23 Naike Bige 24 Jean-Herlé Raphalen Laurent Papazian 25 Antoine Rabbat 26 Michaël Darmon 27 Sylvie Chevret 28 Alexandre Demoule 14
Abstract : Acute respiratory failure (ARF) is the leading reason for intensive care unit (ICU) admission in immunocompromised patients. High-flow nasal oxygen (HFNO) therapy is an alternative to standard oxygen. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates via nasal cannula devices, with FiO2 values of nearly 100%. Benefits include alleviation of dyspnea and discomfort, decreased respiratory distress and decreased mortality in unselected patients with acute hypoxemic respiratory failure. However, in preliminary reports, HFNO benefits are controversial in immunocompromised patients in whom it has never been properly evaluated.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-01790547
Contributeur : Dominique Mornet <>
Soumis le : samedi 18 avril 2020 - 11:16:26
Dernière modification le : jeudi 28 mai 2020 - 16:32:02

Fichier

2018 Azoulay et al., High flow...
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Élie Azoulay, Virginie Lemiale, Djamel Mokart, Saad Nseir, Laurent Argaud, et al.. High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial. Trials, BioMed Central, 2018, 19 (1), pp.157. ⟨10.1186/s13063-018-2492-z⟩. ⟨hal-01790547⟩

Partager

Métriques

Consultations de la notice

514

Téléchargements de fichiers

95